Our test BGaze TDAH validation study has been published in the Journal of Attention Disorders.
Braingaze closely collaborates with several academic hospitals to study and validate our biomarker of attention for the diagnosis of neurodevelopmental disorders.
As a results of these collaborations, Paloma Varela, child and adolescent psychiatrist and Dr. José Cañete, director of the Dept. of Child and Adolescent Psychiatry of the Hospital Mataró, in collaboration with Prof. Dr. Stephen Faraone, of the Upstate Medical University of New York and Prof. Dr. Josep Antoni Ramos-Quiroga, head of the Dept. Psychiatry of the University Hospital Vall d ‘Hebron have been working on the validation of the BGaze biomarker for ADHD in children between 7-14 years of age.
Children with attentional and conduct problems were evaluated with the BGaze test and the results have been compared between ADHD patients, clinical controls and healthy subjects .The results demonstrate a high classification accuracy of the BGaze marker with low false positive and false negatives rates.
The validation study shows that the BGaze test is a reliable and objective tool supporting clinical diagnosis of AHD in children.
The article describing the validation study can be downloaded here